Department of Medicine, Department of
Oncology, and Department of Molecular Biology and Genetics, Graduate
Program in Biochemistry, Cellular, and Molecular Biology, The Johns
Hopkins University School of Medicine, Baltimore, Maryland 21205
Received 13 August 1998/Returned for modification 22 September
1998/Accepted 7 December 1998
 |
INTRODUCTION |
Antigen receptor genes are assembled
during lymphocyte development by a site-specific recombination reaction
known as V(D)J recombination (71). RAG-1 and
RAG-2 are the essential lymphoid-cell-specific components of
the V(D)J recombinase and are required for the initiation of
recombination in developing B and T cells (44, 49, 59, 63).
Rag-1 and Rag-2 proteins are present at significant levels only in
lymphocytes, limiting V(D)J recombinase activity to lymphoid cells.
RAG expression begins at the earliest stages of
lymphocyte development (22, 27, 72, 76). In developing B
cells, RAG transcript levels transiently decrease after
successful immunoglobulin (Ig) heavy-chain gene rearrangement and
increase again during light-chain gene rearrangement in pre-B cells
(22). This pattern of expression has been proposed to
contribute to the allelic exclusion of heavy-chain gene rearrangement
and the temporally regulated activation of light-chain gene
rearrangement. RAG gene transcription persists in surface
IgM-positive (sIgM+) immature bone marrow B cells but is
absent in mature IgD+ peripheral B cells (22).
Recent experiments have revealed two surprising aspects of
RAG transcriptional regulation: (i) RAG transcription increases in immature B cells expressing an autoreactive antigen receptor leading to receptor editing, an important tolerance mechanism in B cells (19, 42, 70); and (ii) RAG
transcription [and V(D)J recombination] is reactivated in germinal
center B cells during an immune response (24, 25, 32, 34,
52). In developing T cells, RAG expression persists in
CD4+ CD8+ CD3+ T cells until
positive selection and subsequent differentiation into CD4 or CD8
single-positive T cells. CD3 cross-linking extinguishes RAG
expression in thymocytes (72, 76). One recent report
suggests that peripheral T cells reactivate the V(D)J recombinase in
the setting of persistent negative selection (41). Thus,
RAG transcription appears to be regulated differently in B
and T cells.
In all species examined thus far, the genomic organization of
RAG-1 and RAG-2 has been conserved, with the two
genes tightly linked and convergently transcribed (60). This
observation led to the hypothesis that the RAG genes derive
from an ancestral transposon that integrated into an early vertebrate
genome (49, 69). With one exception, the coding region of
each gene is contained within a single exon (26). Basal
promoters for murine and human RAG-1 and human
RAG-2 have been described (5, 17, 38, 77). None
of these promoters show tissue specificity, however. The promoters of
the murine and human RAG-1 genes are highly conserved, supporting the idea that the mechanism of their regulation is also conserved.
Elucidating the regulation of RAG gene transcription should
enhance our understanding of lymphoid lineage determination and the
regulation of V(D)J recombination. In addition, defective or aberrant
regulation of RAG transcription may contribute to some cases
of human severe combined immunodeficiency (1) and possibly
to lymphocytic leukemia. In an attempt to first understand the
cis elements that control RAG expression, we have
cloned and characterized the core promoter of the murine
RAG-2 gene. The promoter was active in several pro-B-cell
lines and two T-cell lines but showed little activity in a mature
B-cell line, an immature T-cell line, and nonlymphoid cells. To our
surprise, we found that different factors were responsible for the
activity of the promoter in B and T cells. We have identified a
conserved DNA sequence critical for promoter activity that binds the
B-cell transcription factor BSAP (also known as Pax-5) in vitro and is occupied in a tissue-specific fashion in vivo. An overlapping but
distinct region of the promoter is essential for its activity in T
cells. We found that a more distal region of the RAG-2
promoter dispensable in pro-B cells was quantitatively important in T
cells. The involvement of BSAP in the regulation of RAG-2
transcription may contribute to the differences in RAG gene
expression observed in the T- and B-cell lineages.
 |
MATERIALS AND METHODS |
Cells and cell culture.
Thymocytes and splenocytes were
isolated from 6- to 12-week-old BALB/c mice (National Cancer
Institute). The following cell lines were used: 63-12 (63),
103 bcl2/4 (7), and 220-8 (3), transformed
pro-B-cell lines; WEHI-231, M12 (21), and CH33
(28), mature B-cell lymphomas; 2017 (65), a
transformed immature T-cell line; VL3-3M2, an immature T-cell line
(23); Jurkat and EL4, mature T-cell lymphomas; P815, a
mastocytoma cell line (13); 293T; HeLa; and NIH 3T3. The 103 bcl2/4 line was grown at 33 or 39°C in a 5% CO2
atmosphere in RPMI 1640 (Mediatech) supplemented with 10% fetal calf
serum, penicillin-streptomycin, L-glutamine, and 50 µM
-mercaptoethanol. All other B- and T-cell lines, as well as P815
cells, were grown at 37°C and 5% CO2 in the same medium
except with 5% fetal calf serum. 293T, NIH 3T3, and HeLa cells were
grown in Dulbecco modified Eagle medium (Mediatech) with 4.5 or 1 (HeLa) g of glucose per liter, supplemented with 10% fetal calf serum,
L-glutamine, penicillin-streptomycin, and 50 µM
-mercaptoethanol.
Primer extension.
Fifty nanograms of a 30-mer
oligonucleotide (5'-TCCCTCTCTGAATCCTTTCGGCCAAGCCAG) was end
labeled with [
-32P]ATP (specific activity, 6,000 Ci/mmol; Amersham) and T4 polynucleotide kinase (New England Biolabs)
to a specific activity of 3 × 108 cpm/µg;
105 cpm of this primer was coprecipitated with 40 µg of
total RNA from thymus, 103 bcl2/4 cells grown at 33 or at 39°C for
6.5 h, CH33 cells, or yeast tRNA. Samples were resuspended in 10 µl of 10 mM Tris (pH 8.3)-90 mM KCl-1 mM EDTA, denatured for 3 min
at 94°C, and then annealed 1 h at 64°C. During the last few
minutes of annealing, 40 µl of prewarmed 10 mM Tris (pH 8.3)-90 mM
KCl-1.25 mM MnCl2-1.25 mM dithiothreitol (DTT)-250 mM
deoxynucleoside triphosphates was added to the samples, followed by 2.5 U of
Tth DNA polymerase (Clontech), and incubated 1 h at 70°C. The samples were precipitated, and half of each sample was
run on a 6% polyacrylamide-7 M urea gel alongside a DNA sequencing
ladder as a size marker. The dried gel was exposed to X-Omat AR film
(Kodak) at
80°C with an intensifying screen for 14 days.
S1 nuclease mapping.
A uniformly labeled probe was prepared
as follows. The template for the probe was a plasmid containing an
insert extending from the 3' end of the first exon of RAG-2
to a HindIII site 402 bp upstream cloned into the
XhoI and BglII sites of pGL2-Basic (Promega). Two
micrograms of this plasmid was denatured with 0.2 N NaOH, neutralized,
precipitated, and annealed to 5 pmol of a 25-mer oligonucleotide
(5'-TCCCTCTCTGAATCCTTTCGGCCAA). The primer was extended with
[
-32P]dATP for 30 min with Klenow enzyme, followed by
a 20-min chase with unlabeled dATP. The extended product was linearized
with XhoI digestion, and unincorporated nucleotides were
separated using the Qiaquick nucleotide removal kit (Qiagen). The probe was denatured and gel purified from a 6% polyacrylamide-7 M urea gel.
Probe (5 × 104 cpm) was coprecipitated with 40 µg
of total RNA from thymus, 103 bcl2/4 cells grown at 39°C for 6.5 h, CH33 cells, or yeast tRNA. Samples were resuspended in 80%
formamide-0.4 M
piperazine-N,N'-bis(2-ethanesulfonic acid)
(PIPES; pH 6.4)-0.4 M NaCl-1 mM EDTA, denatured, and hybridized
overnight at 30°C. Digestion was carried out for 1 h at 37°C
with 300 U of S1 nuclease (Life Technologies). Products were
precipitated and loaded onto a 6% polyacrylamide-7 M urea gel
alongside a DNA sequencing ladder as a size marker. The dried gel was autoradiographed.
Cloning and sequencing of the RAG-2 5' flanking
region.
Two P1 clones containing the murine RAG-2 locus
were identified by screening a murine P1 phage genomic library with
RAG-1- and RAG-2-specific PCR primers and
obtained from Genome Systems, St. Louis, Mo. One of these clones was
digested with SacI and subcloned into pBluescript SK
(Stratagene). A subclone with a 17-kb insert was identified as
including the region 5' of the RAG-2 coding exon by Southern
blotting using a RAG-2 cDNA probe. The region upstream and
downstream of the published first exon sequence was sequenced on both
strands by the dideoxy-chain termination method (Sequenase; Amersham).
Plasmid constructs.
An XmnI fragment extending
from ~
900 to +86 of the RAG-2 promoter and a blunted
HindIII-XmnI fragment from
279 to +86 were cloned into the blunted HindIII site of pGL2-Basic
(Promega). PCR was used to amplify a fragment from
279 to +123, which
was cloned into the XhoI and BglII sites of
pGL2-Basic. The NheI-PstI fragment from this
construct was replaced with NheI-PstI fragments from the ~
900 to +86 and
279 to +86 constructs described above to
generate constructs containing sequences from ~
900 to +123 and
279 to +123, respectively. The constructs extending from
71 to
+123,
45 to +123,
23 to +123,
279 to +37, and
71 to
23 were
made using PCR. The construct containing sequences from
279 to +9 was
generated from the
279 to +123 construct by cutting with
PstI and BglII, blunting, and religating. The
(
156/
107) construct was made by first mutating nucleotides
156
to
152 as described below, then cutting with SmaI and
BsmAI, blunting, and religating.
The RAG-1 promoter construct was made by cloning an
EcoRV-PstI fragment extending from
243 to +72
(5) into the polylinker of pGL2-Basic. The simian virus 40 (SV40) promoter construct was pGL2-Promoter (Promega).
Oligonucleotide-directed mutagenesis was used to make five different
5-bp changes in the
279 to +123 construct, using the P-Select/P-Alter
system (Promega). The
143 to
139 sequence was changed to GCCCC.
The eukaryotic BSAP expression construct was created by cloning the
NotI-linkered murine BSAP cDNA (78) into the
EFBneo expression vector (a modified version of pEF-BOS
[43]). The six-His-tagged prokaryotic BSAP expression
construct was created by cloning the same NotI fragment into
the expression vector pET22b (Invitrogen) at its NotI site
and then correcting the reading frame of the fusion protein by
modifying its polylinker. BSAP expression was induced in
Escherichia coli BL21 harboring this plasmid by using 1 mM
isopropyl-
-D-thiogalactopyranoside for 2 h at
30°C. Recombinant BSAP (rBSAP) was purified from bacterial lysates
under mildly denaturing conditions (5 M urea) and renatured while bound
to His-Bind resin (Novagen). The eluted protein (>90% pure as
assessed by gel electrophoresis) was dialyzed against an excess of 20 mM Tris (pH 8.0)-100 mM NaCl-0.1 mM EDTA-1 mM DTT-0.4 mM
phenylmethylsulfonyl fluoride-20% glycerol and stored frozen at
80°C.
Transient transfection reporter assays.
220-8, 103 bcl2/4,
63-12, WEHI-231, and EL4 cells were transfected by the DEAE-dextran
method. First, 107 cells were washed twice in STBS (25 mM
Tris [pH 7.4], 137 mM NaCl, 5 mM KCl, 0.6 mM
Na2HPO4, 0.7 mM CaCl2, 0.5 mM
MgCl2) and resuspended in 1 ml of STBS with 10 µg of
reporter plasmid, 0.5 µg of pCMV-
-gal (Promega), and 250 µg of
DEAE-dextran per ml for 20 min at room temperature. Cells were washed
with medium, resuspended in medium, and grown for approximately 48 h before harvest. 2017, VL3-3M2, Jurkat, M12, P815, and HeLa cells were transfected with Superfect reagent (Qiagen) according to the
manufacturer's instructions. In some experiments, DEAE-dextran was
used for M12 and 2017.
293T and NIH 3T3 cells were transfected by the calcium phosphate-HEPES
method as described elsewhere (4). Cells were grown for
approximately 48 h in the presence of the precipitate before harvest. Ten micrograms of reporter plasmid and 100 ng of pCMV-
-gal were used for each 10-cm-diameter dish.
Cells were harvested as follows. A cell scraper was used to transfer
the adherent cell lines to microcentrifuge tubes. Cells were washed
twice with phosphate-buffered saline (PBS) and lysed for 15 min in
reporter lysis buffer (Promega), vortexed for 15 s, and spun for 2 min at 4°C in a microcentrifuge. Supernatant was combined with
luciferase substrate (Promega), and activity was measured with a
luminometer (Analytical Luminescence Laboratories).
-Galactosidase
assays were performed using the Galacto-Light Plus kit (Tropix)
according to the manufacturer's instructions.
For cotransfection experiments, 10 µg of the
279/+123 reporter and
0.5 µg of empty EFBneo vector or EFBneoBSAP was used. 293T cells were
transfected as described above. Other cell lines were transfected with Superfect.
Luciferase activity for each sample was normalized to the
-galactosidase control. Unless otherwise noted, all experiments were
performed in duplicate or triplicate and repeated two to three times.
EMSA.
For electrophoretic mobility shift assay, (EMSA), the
wild-type and mutant versions of the
103 to
9 RAG-2
promoter probe were prepared by PCR from plasmid DNA templates by using
the primers 5'-CAACCATCACAGGGGTGCAG (top strand) and
5'-GCCTACAGATGTTCCAGTGAG (bottom strand). PCR conditions
were 30 cycles of 94°C for 1 min, 57°C for 1 min, and 72°C for 1 min 15 s, followed by a 10-min final extension at 72°C. Products
were purified from agarose gels with a Qiaex II gel extraction kit
(Qiagen). Approximately 15 ng of probe fragment was end labeled with
[
-32P]ATP for 30 min at 37°C by using T4
polynucleotide kinase (New England Biolabs). Unincorporated nucleotides
were removed by using a spin column (Qiagen).
Nuclear extracts were prepared as described elsewhere (61).
The integrity and relative concentration of each extract were confirmed
by EMSA with a probe that binds the ubiquitous Oct-1 transcription
factor (62).
Each 20-µl EMSA binding reaction mixture consisted of 10 mM Tris (pH
7.5), 1 mM EDTA, 1 mM DTT, 5% glycerol, 1 mg of bovine serum albumin
per ml, 100 µg of poly(dI-dC) (Pharmacia) per ml, approximately 100 pg of probe DNA, 5 µM ZnSO4, and 5 µl of nuclear extract (7 to 15 µg, depending on the source). Recombinant BSAP (~25 ng) was substituted for the nuclear extract in the experiment shown in Fig. 7, lanes 19 to 21. The final salt concentration was 100 mM NaCl. For competition, approximately 100-fold molar excess specific
or nonspecific competitor DNA was added to the reaction. For
competition with wild-type or mutant BSAP and NF-
B double-stranded
oligonucleotides, a 50-, 500-, or 5,000-fold molar excess was used. The
CD19 BSAP,
3' enhancer wild-type and mutant BSAP, and NF-
B
probes have been described elsewhere (36, 57, 62). For
antibody supershift experiments, 1 µl of a 1:10 dilution in PBS of
anti-BSAP(189-391) affinity-purified rabbit polyclonal antiserum
(reconstituted in 100 µl of PBS from 100 µl of lyophilized antiserum) or normal rabbit serum was added to the reaction. Binding mixtures were incubated at room temperature for 20 to 30 min and then
loaded onto 0.25× Tris-borate-EDTA-5% polyacrylamide gels that had
been prerun for 2 h at 170 V. Gels were run for 3.5 to 4 h at
170 V, dried, and exposed to PhosphorImager screens (Molecular Dynamics) overnight.
Methylation interference.
Probes from
103 to
9 labeled
on only one strand were prepared by PCR as described above, using
end-labeled top- or bottom-strand primers. Dimethyl sulfate (DMS)
treatment was performed as described elsewhere (4). Binding
reactions were performed as above for EMSA, except scaled up to 80 µl, with 450,000 cpm of each probe and 20 µl of 220-8 nuclear
extract. Bound and free probe were excised from the gel, electroeluted,
and cleaved with piperidine as described above. Equivalent counts per
minute of bound and free probes were loaded on a 6% polyacrylamide-7
M urea sequencing gel alongside a sequencing ladder. The dried gel was
exposed to a PhosphorImager screen as well as X-ray film, and
ImageQuant software (Molecular Dynamics) was used to confirm
differences in band intensity.
In vivo DMS footprinting.
In vivo and in vitro DMS
treatment, piperidine cleavage, and DNA purification were performed as
described elsewhere (62). We subjected 0.5 to 1.5 µg of
piperidine-treated DNA to ligation-mediated PCR. Primer extension was
performed with the primer listed below as follows: 94°C for 5 min,
48°C for 30 min, and 76°C for 10 min. Double-stranded linker
(45) was ligated to the extension products overnight at
16°C with T4 DNA ligase (New England Biolabs). Amplification of
ligated products was performed with the extension primer (see below)
and the linker primer. Samples were heated to 95°C for 1 to 2 min
before Vent polymerase (New England Biolabs) was added. PCR cycles were
as follows: 95°C for 3 min, 56°C for 2 min, and 76°C for 3 min
for 1 cycle; 16 cycles of 95°C for 1 min, 56°C for 2 min, 76°C
for 3 min 5 s/cycle; final extension for 10 min at 76°C.
5'-end-labeled primer was added for three cycles of 95°C for 1 min,
59°C for 2 min, and 76°C for 10 min. DNA was extracted, precipitated, and resuspended in loading dye. Samples were heated to
90°C for 5 min and run on 6% polyacrylamide-7 M urea sequencing gels alongside a sequencing ladder. Gels were dried and exposed to
PhosphorImager screens. Differences in band intensity were analyzed
with ImageQuant software. The following locus-specific primers were
used: for primer extension, 5'-CCGTCGAGAAGCTTAAGACAGTCATTTT; for amplification, 5'-CAAATCGAGTTTCAATTAGACCTTGTCT;
for end labeling, 5'-GACCTTGTCTTTACAAATGACTGGTATC.
In vitro DMS footprinting.
The wild-type
103 to
6
RAG-2 promoter probe labeled on either strand was generated
by PCR as described above, using kinase-labeled top strand or bottom
strand primers. The probes were purified by electrophoresis on a native
15% polyacrylamide gel and recovered by overnight elution and
precipitation. Probes (100,000 cpm) were incubated with 50 ng of rBSAP
in a buffer consisting of 50 mM sodium cacodylate (pH 8.0), 50 mM NaCl,
1 mM EDTA, 200 µg of bovine serum albumin per ml, and 2 µg of
poly(dI-dC) in a final volume of 30 µl. The binding reaction mixtures
were incubated at room temperature for 30 min, at which time 5 µl of
10% DMS was added. Aliquots of the methylation reactions were taken
after 2, 5, and 10 min and quenched by addition of 6 µl of a mixture
of 1.5 M sodium acetate and 1 M
-mercaptoethanol. Carrier tRNA was
added, and the methylated probes were precipitated three times with
ethanol. Methylated DNA was cleaved by reaction with 1 M piperidine at 90°C for 10 min, followed by three cycles of lyophilization and resuspension in double-distilled H2O. Finally, samples were
resuspended in a formamide-containing gel loading buffer, denatured by
heating to 90°C, and then analyzed by electrophoresis through a
denaturing 10% polyacrylamide gel alongside a series of DNA sequencing
reactions using the same radiolabeled primer. Controls included
unmethylated probe DNA and DNA methylated in the absence of rBSAP.
 |
RESULTS |
Mapping RAG-2 transcription initiation sites.
To
obtain genomic sequences including the transcription initiation region
of RAG-2, a murine P1 phage genomic library was screened by
PCR using primers for RAG-1 and RAG-2 coding
sequences. A positive P1 clone was further subcloned, and sequences 5'
of the RAG-2 coding exon were identified by Southern
hybridization with a RAG-2 cDNA probe. Restriction mapping
of this subclone revealed the most 5' exon of RAG-2 to be
approximately 5 kb upstream of the coding exon (data not shown).
Primer extension and S1 nuclease protection assays were used to map
RAG-2 transcription initiation sites (Fig.
1). Sources of RNA included 103 bcl2/4
cells cultured at 33 or 39°C, thymus, CH33 (a mature B-cell line),
and yeast tRNA. 103 bcl2/4 is a conditionally transformed murine bone
marrow pro-B-cell line previously shown to induce RAG-1 and
RAG-2 transcription upon shift to restrictive growth
conditions (7). With both assays, we observed multiple bands
specific to the thymus and induced 103 bcl2/4 samples. The predominant
start site, indicated by the arrow in Fig. 1, was identical in both
analyses, and the patterns of start site usage were very similar
between the thymus and B-cell samples.

View larger version (141K):
[in this window]
[in a new window]
|
FIG. 1.
Mapping of RAG-2 transcription initiation
sites. (A) Primer extension. Total RNA from RAG-2
low-expressing 103 bcl2/4 cells grown at 33°C (lane 1),
high-expressing 103 bcl2/4 cells grown at 39°C (lane 2),
nonexpressing CH33 mature B cells (lane 3), or yeast tRNA (lane 4) was
annealed to an end-labeled primer complementary to sequence in the
first untranslated exon of RAG-2 and extended with
Tth DNA polymerase. Extension products were run on a
sequencing gel alongside a sequencing ladder. An autoradiograph of the
dried gel is shown. Bands corresponding to multiple transcription
initiation sites are seen in the high-expressing sample (lane 2). The
major start site is indicated by an arrowhead. (B) S1 nuclease
protection. Total RNAs from RAG-2-expressing 103 bcl2/4
cells grown at 39°C (lane 1) and thymocytes (lane 2), nonexpressing
CH33 cells (lane 3), and yeast tRNA (lane 4) were hybridized to a
uniformly labeled, complementary single-stranded DNA probe, followed by
S1 nuclease digestion. Digested products were loaded onto a sequencing
gel alongside a sequencing ladder. An autoradiograph of the dried gel
is shown. Multiple transcription start sites are observed. An arrowhead
indicates the major start site.
|
|
We determined the DNA sequence of the first exon and 280 bp 5' of the
major transcription initiation site (Fig.
2). There is a canonical splice donor
site at the intron/exon junction. The predominant transcription start
site as determined above is designated +1. There is no TATA motif
upstream of any of the start sites. Several start sites (those at
65,
33, and +1) are six-of-seven matches to the initiator element
consensus sequence [5'-YYA(+1)NA/TYY-3' (14)], and the site at
46 is a perfect match.
Database searching revealed a number of potential transcription factor
binding sites in the sequence (29), including several that
are involved in the transcription of lymphocyte-specific genes. These
include an E box (consensus CANNTG) at
19, two c-ets-2 sites at
72
and +46 (consensus CTTCCC), a PU.1 site at
133 (AGAGGAACT),
an Sp1 site at
82 (GGAGGGG), and an Ikaros site at
49 (YGGGAW). There are two myb sites (YAACKG) at
46 and
55.
Overall there is a high degree of sequence identity (67% in the
regions between
279 and +123) between the mouse and human genomic
sequences (Fig. 2) (77). Of the potential transcription
factor binding sites, only the Ikaros and myb sites, the E box, and the
c-ets-2 site in the exon are conserved between species.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of the genomic sequence of the murine and
human RAG-2 promoter regions. Sequences of the first exon
and 5' and 3' flanking regions are shown. The human sequence has been
published (77). The intronic sequence is in lowercase. The
major transcription initiation site is numbered +1. Minor transcription
initiation sites are indicated by asterisks. Potential transcription
factor binding sites are underlined, with the BSAP site shown in
boldface.
|
|
RAG-2 promoter activity is cell type specific.
Using a luciferase reporter construct, we tested sequences 279 bp 5' of
and including the first untranslated exon of RAG-2 (
279 to
+123) for functional promoter activity by transient transfection into a
variety of lymphoid and nonlymphoid cell lines (Fig.
3 and Table
1). Each construct was transfected in
duplicate or triplicate in each experiment, and each experiment was
performed multiple times. Luciferase assay values were normalized to
-galactosidase levels from cotransfected plasmid pCMV-
-gal to
control for transfection efficiency. The activity of each construct was
calculated relative to that of the promoterless pGL2-Basic vector. For
comparison, we also tested constructs containing the SV40 promoter and
the murine RAG-1 promoter (
243/+72 [5])
(Fig. 3). The SV40 and RAG-1 promoters were active in every
cell type tested, consistent with the observed lack of tissue
specificity of the RAG-1 promoter (5, 38, 77).
The RAG-1 promoter was more than twice as strong in 293T
cells (an embryonal kidney cell line) as in several pro-B-cell lines.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Relative transcriptional activity of the SV40,
RAG-1, and RAG-2 promoters in 220-8 pro-B cells,
Jurkat T cells, and 293T embryonal kidney cells. Activity is expressed
as fold increase in luciferase activity relative to the promoterless
pGL2-Basic construct. This promoterless vector resulted in uncorrected
light units in the ranges of 1,393 to 1,450 in 220-8 cells, 561 to 723 in Jurkat cells, and 109,337 to 123,208 in 293T cells. The relative
values shown are adjusted for transfection efficiency by using
-galactosidase and represent averages of two or more experiments,
each performed in duplicate.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Relative transcriptional activity of the SV40,
RAG-1, and RAG-2 promoters in B-, T-, and
nonlymphoid cell lines
|
|
In contrast, the RAG-2 promoter was 7- to 19-fold more
active in a panel of pro-B-cell lines compared with 293T cells (Table 1). Interestingly, both RAG-1 and RAG-2 promoter
activity increased when transfected 103 bcl2/4 cells were cultured at
the nonpermissive temperature (Table 1). The RAG-2 promoter
was active in the immature B-cell line WEHI 231, which expresses the
endogenous RAG-2 gene (data not shown), but showed only weak
activity in M12, a mature B-cell lymphoma which lacks endogenous
RAG-2 expression (Table 1), suggesting that the
RAG-2 promoter may contribute to the developmental stage
specificity of RAG-2 expression.
We tested the RAG-2 promoter in several T-cell lines and
found it to be highly active in Jurkat and much less active in EL-4. Although both of these cell lines have been reported to lack
RAG expression (49, 59), reverse
transcription-PCR analysis revealed that Jurkat cells express
significant amounts of endogenous RAG-2 mRNA (data not shown
and reference 18). Surprisingly, the
RAG-2 promoter was essentially inactive in 2017, an Abelson
virus-transformed immature T-cell line reported to have detectable
recombinase activity (65).
Although the RAG-2 construct had some activity in
nonlymphoid cell lines, it was much less than that observed in lymphoid cell lines. To investigate the possibility of a repressor element within the promoter and first exon, 5' and 3' truncation constructs were also tested in 293T cells. No derepression was observed when a
construct corresponding to the minimal core promoter (
71 to +37) was
used (see below; data not shown). In summary, unlike the
RAG-1 promoter, the RAG-2 promoter shows
lymphoid-cell-specific transcriptional activity.
DNA sequences required for RAG-2 promoter
activity.
We generated an extensive series of 5' and 3'
truncations of the RAG-2 promoter and analyzed their
activity by transfection into the pro-B-cell line 220-8 and the T-cell
line Jurkat (Fig. 4). Near-maximal
activity in both cell types was observed with a construct extending
from
279 to +123. This construct gave a signal 12-fold above the
promoterless vector background in 220-8 cells and 100-fold above the
background in Jurkat cells. A construct including approximately 600 bp
of additional upstream sequence had somewhat less promoter activity in
220-8, eightfold above background (Fig. 4A). A 5' deletion extending to
nucleotide
71 did not affect promoter activity in 220-8 (or in other
pro-B-cell lines [data not shown]) but resulted in a 70% decrease in
promoter activity in Jurkat (and VL3-3M2 [data not shown]). Further
deletions and point mutations localized this T-cell-specific promoter
element to a region between nucleotides
156 and
107, with much of
the activity dependent on the integrity of nucleotides
143 to
139 (Fig. 4B). Further truncation from the 5' end to
45 reduced promoter activity by 75% in 220-8 and greater than 90% in Jurkat cells (and
VL3-3M2 [data not shown]). Thus, a DNA sequence between nucleotides
71 and
45 is important for promoter activity in both B- and T-cell
lines. From the 3' end, constructs could be truncated to +37 without
significant loss of activity. Further truncation to +9 resulted in a
64% reduction in promoter activity, however. In summary, the minimal
RAG-2 promoter active in pro-B cells contains sequences
between
71 and +37 while the minimal sequences required in Jurkat
cells extend upstream to position
156.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Delineation of critical sequences in the
RAG-2 promoter in 220-8 pro-B cells (A) and Jurkat T cells
(B). Activity is expressed as fold increase in luciferase activity
relative to the 279/+123 construct. The values shown are adjusted for
transfection efficiency by using -galactosidase and represent
averages of two experiments, each performed in duplicate. The
RAG-2 promoter sequences contained in each construct are
indicated beneath each column. The ( 156/ 107) construct is the
279/+123 construct with an internal deletion of base pairs 156 to
107. The mut 143/ 139 construct is the 279/+123 construct with a
5-bp mutation from 143 to 139.
|
|
Factor binding to the RAG-2 core promoter.
To
identify nuclear factors capable of binding to RAG-2
promoter regulatory elements, EMSAs were performed with a probe which spans a portion of the functionally important pro-B-cell core promoter
region (
103 to
9). As shown in Fig.
5A, a single DNA-protein complex was
detected in nuclear extracts prepared from pro-B (220-8 and 103 bcl2/4)-, immature B (WEHI 231)-, and mature B (M12)-cell lines, as
well as from spleen. This complex was not seen in nuclear extracts
prepared from T-cell lines (2017, Jurkat, VL3-3M2, and EL4), thymus, or
nonlymphoid cell lines (NIH 3T3 and 293T). All extracts demonstrated
similar binding activities in assays using a control probe containing
the binding site for Oct-1 (data not shown). The complex was
specifically competed with excess unlabeled DNA identical in sequence
to the probe but not with an equivalent molar excess of an unrelated
DNA fragment (Fig. 5B). No additional complexes were observed with
probes extending through the rest of the minimal core promoter region
(to +37).

View larger version (120K):
[in this window]
[in a new window]
|
FIG. 5.
A B-cell-specific nuclear factor binds to the core
RAG-2 promoter. (A) EMSA of a RAG-2 core promoter
probe. An end-labeled probe spanning nucleotides 103 to 9 was
incubated with nuclear extracts from B-cell lines (lanes 1 to 3, 10, and 11), T-cell lines (lanes 4, 5, 13, and 14), thymus (lanes 6 and
12), spleen (lane 7), and nonlymphoid cell lines (lanes 8 and 9). The
binding reaction was analyzed by electrophoresis on a nondenaturing
acrylamide gel, which was dried and exposed to a PhosphorImager screen.
A B-cell-specific complex is indicated by the arrow. The integrity and
relative concentration of the extracts were confirmed in separate
assays with a probe binding the ubiquitous Oct-1 transcription factor
(data not shown). (B) Specificity of the B-cell-specific complex. EMSA
was performed as for panel A, using 220-8 nuclear extract and the
RAG-2 promoter 103 to 9 probe. Either no competitor
(comp.) DNA (lane 1) or a 100-fold molar excess of unlabeled DNA
unrelated in sequence to the probe (lane 2; RAG-2 promoter
nucleotides 199 to 103) or identical in sequence to the probe (lane
3; nucleotides 103 to 9) was added to the binding reaction. A
PhosphorImager exposure of the dried gel is shown.
|
|
Methylation interference analysis was performed to identify essential
DNA-protein contacts within the B-cell-specific complex (Fig.
6). Methylation at several G residues on
the bottom strand of the sequence interfered with protein binding.
Fewer contacts were made on the top strand. The binding site as
discerned by this method spans at least 16 bp and is localized to a
region shown to be critical for promoter activity in the transient
transfection reporter construct assay (Fig. 4A; bp
66 to
51).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Methylation interference analysis of the EMSA complex.
Top- and bottom-strand end-labeled versions of the 103 to 9 EMSA
probe were treated with DMS, purified, and incubated with 220-8 nuclear
extracts. The bound and free probes were excised from a nondenaturing
gel, electroeluted, and cleaved at methylated G residues with
piperidine. Single-stranded, end-labeled cleavage products were
analyzed by electrophoresis on a sequencing gel alongside a sequencing
ladder (not shown). An autoradiograph of the dried gel is shown.
Differences in band intensity greater than sample variability in
loading were confirmed by using ImageQuant software. Open circles, G
residues whose methylation interferes with protein binding; filled
circles, G residues whose methylation enhances protein binding. The
pattern of interaction between the protein and its binding site is
summarized at the bottom.
|
|
BSAP binds to the RAG-2 core promoter and is critical
for its function.
Because the promoter binding activity was B cell
specific and encompassed a rather large sequence, we asked whether it
might contain BSAP (Pax-5), a transcription factor expressed only in B
cells, the central nervous system, and testis (2). As shown in Fig. 7A, formation of the EMSA complex
was competed by well-characterized BSAP sites from the Ig
3'
enhancer (57) and the CD19 promoter (36) but not
by large molar excesses (>5,000 fold) of a
3' enhancer site mutant
that no longer binds BSAP (57) or an irrelevant NF-
B
binding site. In addition, polyclonal rabbit anti-BSAP antiserum, but
not preimmune rabbit serum, caused a supershift of the complex (compare
lanes 12 and 13). Taken together, the expression pattern, competition,
and supershift data demonstrate that BSAP binds to a critical element
in the RAG-2 promoter.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 7.
BSAP binds to a conserved element in the
RAG-2 promoter. (A) Competition, antibody supershift, and
mutational analysis of the B-cell-specific complex. EMSA was performed
as for Fig. 5, using either 220-8 nuclear extract (NE) (lanes 1 to 18)
or purified rBSAP (lanes 19 to 21) and either the wild-type (wt) 103
to 9 probe (lanes 1 to 13 and 18 to 21) or probes containing the
mutations (mut) shown in panel B (lanes 14 to 17). Binding reactions
contained no competitor (comp.) DNA (lanes 1 and 12 to 19) or the
indicated molar excesses of unlabeled DNA containing previously
characterized binding sites for BSAP from the Ig 3' enhancer (lanes
2 to 4) and the CD19 promoter (lanes 8 to 10), a mutant version of the
enhancer BSAP site that no longer binds BSAP (lanes 5 to 7), the
wild-type RAG-2 promoter (lane 20), the RAG-2
promoter with a BSAP site mutation (lane 21), or an NF- B site (lane
11). Antibody supershift experiments were performed by adding either
affinity-purified rabbit polyclonal anti-BSAP antiserum (lane 12) or
preimmune rabbit serum (lane 13) to the binding reactions. Solid arrow,
B-cell-specific complex; open arrow, supershifted complexes. (B)
Comparison of the RAG-2 promoter BSAP site with the BSAP
consensus sequence. The sequence shown is the complementary strand of
the published consensus (9). Nucleotides above the consensus
represent alternative nucleotides at each position, with lowercase
letters representing nucleotides found in that position at a frequency
of less than 30%. Also indicated are mutations analyzed by EMSA in
panel A and by transfection in Fig. 8A.
|
|
Our gel shift probe contains potential binding sites for other factors
in addition to BSAP (Fig. 2). To determine whether the BSAP-containing
gel shift complex described above contains other factors as well, we
compared its mobility to that of a complex generated by using
His-tagged rBSAP purified from E. coli. The bacterially
produced BSAP generated a specific DNA-protein complex (Fig. 7A, lanes
19 to 21). This complex migrated slightly more slowly than a complex
generated on the same probe, using 220-8 pro-B-cell nuclear extract
(lane 18). This mobility difference can be accounted for by the
additional amino acids introduced into the rBSAP by the expression
vector (see Materials and Methods). Thus, we conclude that BSAP is the
only protein within this specific pro-B-cell gel shift complex.
The BSAP DNA binding consensus consists of two half-sites, which
contribute independently to binding affinity (10). No
naturally occurring BSAP site completely conforms to the consensus
(9). The RAG-2 promoter binding site contains a
TAC trinucleotide in the 3' half-site instead of the usual TGC, but the
presence of an A in this position has been shown to preserve the
ability of a site to bind BSAP (57, 66). There is an exact
match to the GTCAC in the 5' half-site consensus (Fig. 6B). Further
evidence for the significance of this BSAP site is our observation that the murine and human RAG-2 promoter sequences are identical
from positions
70 to
50 (Fig. 2).
To further characterize the functional importance of the BSAP site, we
generated a series of 5-bp substitution mutations across this interval
(Fig. 7B). Mutation of base pairs
70 to
66,
65 to
61, or
60
to
56 abolished the binding of BSAP to the RAG-2 promoter
probe, whereas binding was unaffected by mutation of bp
54 to
50
(Fig. 7A). These same mutations were introduced into the
279/+123
RAG-2 reporter construct and assayed by transient transfection into 220-8 cells. The mutations that abolished BSAP binding in the gel shift decreased promoter activity by 60 to 75%,
whereas the mutation that preserved binding had little effect on
promoter activity (Fig. 8A). When we
tested each of these mutants by transfection into Jurkat T cells, we
observed a different pattern of activity (Fig. 8A). While mutant 1 decreased promoter activity in 220-8 by approximately 60%, it had no
effect in Jurkat. Conversely, mutant 4 had little effect on
transcription in 220-8 but resulted in a 50% decrease in promoter
activity in Jurkat. The latter mutation disrupts both the Ikaros site
and one of the Myb sites in this region (Fig. 2), suggesting that these
factors may contribute to core promoter activity in T cells but not B
cells.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 8.
BSAP is a critical and potent activator of the
RAG-2 promoter. (A) Transient transfection reporter assay
comparing the four mutants described in Fig. 7B to the wild-type
promoter. The mutations were introduced into the 279/+123 promoter
construct, and the experiments were performed in 220-8 cells and Jurkat
T cells. Activities of the mutants are depicted relative to the
wild-type activity, which is assigned a value of 1. The results shown
are the average of three (220-8) or five (Jurkat) experiments, each
performed in duplicate and adjusted for transfection efficiency by
using -galactosidase. (B) Effect of BSAP expression vector
cotransfection on RAG-2 promoter activity. The cell lines
indicated were cotransfected with the 279/+123 reporter construct and
either empty expression vector or BSAP expression vector. The results
are depicted as the fold increase in luciferase activity by BSAP
compared to empty vector. Data shown are from one representative
experiment performed in duplicate and adjusted for transfection
efficiency.
|
|
Because BSAP has been shown to have either transcriptional activating
or repressing functions, depending on context, we performed cotransfection experiments to determine whether BSAP could
transactivate the RAG-2 promoter. Cell lines were
cotransfected with the
279/+123 RAG-2 promoter reporter
construct and either empty expression vector or a murine BSAP
expression vector. Figure 8B shows the fold increase in reporter
activity over empty vector conferred by BSAP expression. The effects of
BSAP expression varied depending on the recipient cell line. In 2017 cells, which had very low levels of activity with the RAG-2
promoter reporter in the absence of exogenous BSAP (Table 1), BSAP
expression caused a 300-fold increase in promoter activity. M12 cells,
which also had low activity in the absence of exogenous BSAP, showed a
14-fold induction by BSAP. Expression of BSAP in 220-8 and 293T cells
had little effect. Interestingly, the effect of BSAP cotransfection in
lymphoid cell lines appears to be inversely proportional to the amount
of BSAP present in the untransfected cell line. 220-8 cells have
severalfold more BSAP than M12 cells (data not shown), while 2017 cells
have no BSAP. 293T cells also lack BSAP, however, and the failure of BSAP cotransfection to induce the RAG-2 promoter construct
must be due to other causes (see Discussion). We believe that these experiments represent direct effects of BSAP on the RAG-2
promoter since BSAP-site mutant reporter constructs show significantly less stimulation in these cotransfection experiments (data not shown).
To determine whether BSAP might regulate the endogenous
RAG-2 promoter in vivo, we performed in vivo DMS
footprinting on 220-8 and 103 bcl2/4 pro-B cells, thymocytes, the
T-cell line VL3-3M2, and the nonlymphoid mastocytoma cell line P815. As
shown in Fig. 9, the G at position
54
within the BSAP site on the bottom strand exhibits enhanced DMS
reactivity relative to in vitro-treated DNA specifically in pro-B cells
but not in thymocytes, VL3-3M2, or P815 cells. No footprint was
detected on the top strand. Interestingly, the in vivo BSAP site
footprint does not change when 103 bcl2/4 cells are cultured under
restrictive conditions. Thus, the RAG-2 promoter BSAP site
is occupied in vivo in pro-B cells.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 9.
The RAG-2 promoter BSAP site is occupied in
vivo in pro-B cells. (A) In vivo DMS footprinting of the
RAG-2 promoter. Intact 220-8 or 103 bcl2/4 pro-B cells, P815
mastocytoma cells, thymocytes, VL3-3M2 T cells, or purified DNA
isolated from 220-8 cells or thymocytes was treated with DMS. The
purified DNA was subjected to piperidine cleavage at methylated G
residues, linker ligation, and PCR amplification with nested
locus-specific primers and a linker-specific primer. Labeled extension
products were analyzed on a sequencing gel alongside a sequencing
ladder, and the dried gel was exposed to a PhosphorImager screen. The
bottom strand of the promoter is analyzed in the experiments shown.
Lanes 1 to 7 and 8 to 10 represent two separate experiments. The black
circle indicates the G at 54 which is hypersensitive in vivo to DMS
in the 220-8 and 103 bcl2/4 cells. (B) Histograms of lanes 2, 6, and 7. ImageQuant software was used to quantify the peak intensities of the
footprint ladders shown in panel A. The absolute intensities of the
peaks differ among the samples, but significant differences in relative
peak intensities are indicated. The G residue at 54 is hypersensitive
in 220-8 cells in comparison to thymocytes and purified DNA.
|
|
While this in vivo footprinting analysis revealed a correlation between
DMS hyperreactivity at nucleotide
54 of the RAG-2 promoter, the presence of BSAP, and the activity of the
RAG-2 promoter reporter construct in pro-B-cell lines, this
experiment does not allow us to conclude that BSAP binding is
responsible for the in vivo footprint. To determine whether the DMS
hyperreactivity that we observed was caused by BSAP binding, we
performed in vitro DMS footprinting on a radiolabeled RAG-2
promoter probe (
103 to
9), using purified recombinant BSAP (Fig.
10). This analysis revealed that the
same nucleotide within the RAG-2 promoter which was
hypersensitive to DMS within pro-B cells in vivo (
54) was also
rendered hypersensitive upon interaction with rBSAP in vitro (compare
lane 2 with lanes 3 and 4). We failed to observe any additional
enhanced or diminished bands on either strand of this probe (Fig. 10
and data not shown). Thus, we conclude that BSAP is bound to a critical
region of the RAG-2 promoter in progenitor B-cell lines in
vivo.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 10.
In vitro DMS footprinting of the RAG-2
promoter. (A) Double-stranded DNA consisting of the 103 to 9 region
of the RAG-2 promoter was labeled on the bottom strand by
PCR using a kinase-labeled primer and incubated in vitro with buffer
(lane 2) or with purified rBSAP (lanes 3 and 4). The DNA-protein
complexes were then treated with DMS for either 2 min (lanes 2 and 3)
or 5 min (lane 4), repurified, and finally reacted with piperidine to
cleave methylated G residues. The samples were then analyzed by
denaturing polyacrylamide gel electrophoresis alongside a DNA
sequencing ladder of the same region generated by using the same
kinase-labeled primer (lanes labeled G, A, T, and C). A phosphorimage
of the gel is shown. Lane 1 contains radiolabeled probe which was not
reacted with DMS. The location of the BSAP binding site is indicated
along with the location of the hypersensitive site observed in vivo at
54 (Fig. 9). Note that the orientation of this direct analysis of the
bottom strand of the promoter is the reverse of that generated by the
indirect technique of in vivo footprinting. (B) ImageQuant-generated
tracings of lanes 2 and 3. The position of the hypersensitive
nucleotide indicated.
|
|
 |
DISCUSSION |
Understanding the transcriptional regulation of the RAG
genes is likely to provide important insights into the control of lymphocyte development and differentiation. As a step toward this goal,
we have cloned and characterized the promoter of the murine RAG-2 gene. Using a transient transfection assay, we defined
a 193-bp core RAG-2 promoter, within which three regions
(
156 to
107,
71 to
45, and +9 to +37) contribute most of the
activity (Fig. 4). We found the
156 to
107 region to be dispensable
for promoter activity in B cells but important in T cells. The
71 to
45 region was important for transcription in both cell types but
apparently interacts with distinct factors in B and T cells. Our
finding that the region between +9 and +37 contributes to promoter
activity was of interest since sequences in the RAG-1 untranslated exon have also been shown to be critical for basal promoter function (5).
The core RAG-2 promoter demonstrated tissue specificity,
with greatest activity in pro-B-cell lines and two T-cell lines and little or no activity in a mature B-cell line and several nonlymphoid cell lines. Surprisingly, the promoter was inactive in an immature T-cell line, 2017, which expresses the endogenous RAG-2
gene. Unlike most available T-cell lines, however, 2017 was transformed by the Abelson leukemia virus and thus might display unusual
transcriptional regulatory properties (35, 65).
We found that a region within this promoter which is essential for its
function binds to the B-cell transcription factor BSAP (Pax-5).
Disruption of the BSAP binding site by site-directed mutagenesis
significantly diminished promoter activity in pro-B cells (Fig. 8).
Although the same general region was also important for promoter
activity in T cells, analysis of a panel of specific mutants revealed
the critical sequences to differ between B and T cells. Cotransfection
of a BSAP expression vector into immature T-cell and mature B-cell
lines resulted in dramatic increases in promoter activity, whereas BSAP
cotransfection did not activate the promoter in nonlymphoid cells. The
biological significance of these observations was heightened by the
results of footprinting analyses which indicated that this BSAP site
was occupied in vivo within B-lineage cells expressing RAG-2
and that the in vivo footprint was a consequence of BSAP binding (Fig.
9 and 10).
RAG-2 transcription initiation.
RAG-2
transcription initiates from multiple sites clustered within a 90- to
100-bp region. In this respect the murine RAG-2 gene differs
from the human RAG-2 gene, which initiates transcription from one predominant site (77). The difference between the
two species is curious because there is a high level of sequence
identity over the region from which transcription initiates, which
suggests similar transcriptional control mechanisms. The major start
site that we observed does correspond closely to the major human start site, however. The RAG-2 promoter lacks a TATA sequence, but
several of the initiation sites are close matches to the consensus
sequence for the initiator element. Multiple start sites and absence of a TATA box are characteristics shared by several other early
lymphocyte-specific promoters, including the RAG-1 (5,
17, 38, 77), VpreB (50),
5
(37), B29 (30, 68), blk
(79), and CD19 (36) promoters.
Tissue specificity of the RAG-2 promoter.
To
assess its potential contribution to the tissue specificity of
RAG-2 expression, we tested the activity of the
RAG-2 promoter construct in various B- and T-cell lines,
including 220-8, 63-12, and 103 bcl2/4 (pro-B), VL3-3M2 and 2017 (immature T), Jurkat and EL-4 (mature T), WEHI 231 (immature B), M12
(mature B), 293T (embryonal kidney), P815 (mastocytoma), HeLa (cervical
carcinoma), and NIH 3T3 (fibroblast). The promoter showed extremely low
but reproducible activity in each of the nonlymphoid cell lines,
severalfold lower than that observed in pro-B cells. In addition, it
was inactive in mature B- and T-cell lines lacking in RAG
expression. These differences become even more dramatic when compared
to transcription driven by the SV40 and RAG-1 promoters in
these same cell lines. As others have shown, the RAG-1
promoter has significant activity in nonlymphoid cells and in a mature
B-cell line (5, 17, 38, 77). Despite the coordinate and
equally specific transcription of these two genes, the RAG-2
promoter confers a degree of tissue and developmental stage specificity
that the RAG-1 promoter does not.
While the RAG-2 promoter was active in both pro-B- and
T-cell lines, we found that different elements within the promoter were
important in these two lineages. An upstream region extending from
nucleotides
156 to
107 was important in T cells and had no apparent
effect in pro-B cells. We have thus far been unable to identify the
factors that may interact with this region of the promoter in T cells.
It is possible that this region of the promoter will prove to be
important for RAG-2 expression in primary B-cell progenitors
but that some aspect of cell transformation interferes with its
activity. In this regard, it is worth noting that RAG-2
promoter activity in Jurkat T cells is 5- to 10-fold greater than in
various pro-B- and immature B-cell lines. Finally, it remains possible
that additional DNA sequences important for promoter activity in vivo
are not revealed by these assays using transformed cell lines.
We found that the region between
71 and
45 is important for
RAG-2 promoter activity in both lymphoid lineages. This
region contains potential binding sites for BSAP, Ikaros, and myb. As described below, we demonstrated that BSAP is critical for promoter activity in transfected pro-B-cell lines but not in T-lineage cells
(BSAP is not expressed in T cells). Ikaros and myb, however, are
essential factors expressed at multiple stages of B- and T-cell development (20, 40). It is possible that these latter
factors drive constitutive promoter activity at multiple stages of B- and T-cell development, but that BSAP is involved in the
B-cell-specific regulation of RAG-2 transcription (see below).
A BSAP site in the core RAG-2 promoter is critical for
its activity in B cells.
We found that an essential region of the
RAG-2 promoter specifically interacts with the
well-characterized transcription factor BSAP. BSAP, a member of the Pax
family of transcription factors, is expressed primarily in B cells, the
central nervous system, and testis (6). BSAP is found in all
stages of B-cell development except plasma cells. Several
B-cell-specific genes have been implicated as targets for BSAP
activation, including CD19 (36), blk
(79), VpreB, and
5 (51),
mb-1 (16), and XBP-1 (54),
as well as the germ line Ig heavy-chain C
promoter (58).
Interestingly, many of these genes have multiple transcription start
sites and lack a TATA box. This may be coincidence, or BSAP may play a
role in recruiting the basal transcription machinery to TATA-less
promoters in B cells. In addition BSAP has been shown or suggested to
act as a repressor at the heavy-chain 3'
enhancer (47,
64), the kappa light-chain 3' enhancer (57, 62), and
the J-chain gene promoter (55).
BSAP and the regulation of the core RAG-2
promoter.
The expression of BSAP DNA binding activity among the
group of B-cell lines used in this study parallels the activity of the RAG-2 promoter in these cells. Our observation that
cotransfection of a BSAP expression vector led to a dramatic increase
of RAG-2 promoter activity in the immature T- and mature
B-cell lines verifies BSAP's role as a transactivator of
RAG-2 transcription in lymphocytes. Interestingly,
cotransfection of the BSAP expression vector into 293T cells failed to
activate the RAG-2 promoter construct. We can envision
several potential mechanisms for this tissue-specific effect: (i)
another factor(s) present in B and T cells is required to cooperate
with BSAP; (ii) BSAP is posttranslationally modified in a
lymphoid-cell-specific fashion, enabling it to transactivate; or (iii)
there is a repressor or silencer element within the minimal core
promoter region that is active in nonlymphoid cells. Others have
observed the failure of cotransfected BSAP to activate a reporter
construct in nonlymphoid cell lines (2, 56). However, cotransfected BSAP was able to activate a construct with two BSAP sites
upstream of a TATA-containing minimal promoter in HeLa cells, making
possibility ii above unlikely and suggesting that more stringent
demands are placed upon BSAP by TATA-less promoters (56).
Mice lacking BSAP have been generated using homologous recombination in
embryonic stem cells (73). These mice exhibit a complete
lack of detectable B-cell progenitors in the fetal liver, whereas bone
marrow B cells develop to the early pro-B stage (B220+
CD43+
5+ VpreB+
HSA+ BP1
) (48). These pro-B cells
express normal levels of RAG-1 and RAG-2 and
contain numerous D-to-JH rearranged Ig heavy-chain loci. Thus, it appears from this result that BSAP is not required for B-cell-specific RAG-2 expression in vivo. There are several
ways to reconcile this report with the data presented here. First, BSAP
may be important but not essential for bone marrow RAG-2 expression. Second, the BSAP-deficient mice may compensate for the loss
of BSAP expression through the activity of another Pax family member.
Pax-2 and Pax-8, which are most closely related to BSAP and bind to the
same consensus sequence, are not expressed in the spleen (12, 15,
53), but there are no data in the literature regarding their
expression in bone marrow B cells. It is even possible that a currently
unknown Pax family member is present in B cells and capable of
substituting for BSAP at the RAG-2 promoter. Finally, it is
possible that BSAP is necessary for regulated RAG-2
expression only during the later stages of B-cell development.
There are three circumstances where there might be a role for a
B-cell-specific RAG-2 regulator such as BSAP. First, early pre-B cells contain very little RAG-1 or RAG-2
mRNA (22). RAG expression is reactivated,
however, in small resting pre-B cells. This modulation of
RAG expression has been suggested to play a role in
heavy-chain gene allelic exclusion. Second, immature B cells in the
bone marrow expressing an autoreactive antigen receptor can undergo
receptor editing mediated by increased recombinase expression (19,
42, 70). Finally, germinal center B cells have also recently been
shown to reactivate RAG expression and functional
recombinase activity upon antigen stimulation (24, 25, 31, 32,
52). Interestingly, these cells also reactivate transcription of
5 (24), which has been suggested to be a target for
regulation by BSAP. Each of these circumstances occurs after the block
in B-cell development observed in mice lacking BSAP. Thus, the
persistence of RAG expression in BSAP-deficient pro-B cells
does not rule out a later role for BSAP. Other experimental approaches
will be required to test this hypothesis.
Since the initial submission of this paper, a report supporting a role
for BSAP in the regulation of RAG expression in vivo has
been published. Verkoczy and Berinstein used differential display to
compare gene expression between two clonally related variants of a
mature B-cell line, one of which expressed approximately 10-fold more
RAG-1 and RAG-2 than the other; BSAP was cloned
as a transcript whose expression correlated with high levels of
RAG transcription (74). Aside from providing
evidence that BSAP may regulate the endogenous RAG-2 gene,
it is interesting that the cell line used in the study is a mature
B-cell line that undergoes spontaneous secondary light-chain
rearrangements in culture, again supporting a role for BSAP in receptor
editing or germinal center RAG reexpression.
There is considerable evidence for a role for BSAP in several events
during later stages of B-cell development (6).
Overexpression of BSAP in plasma cell lines or resting splenic B cells
induced proliferation, whereas down-regulation of BSAP by specific
antisense oligonucleotides greatly diminished proliferation mediated by a variety of stimuli and also decreased lipopolysaccharide (LPS)- and
interleukin-4 (IL-4)-induced Ig class switching (75). BSAP has been shown by similar approaches to repress the activity of the Ig
heavy-chain 3'
enhancer and the J-chain promoter during B-cell
development up to the plasma cell stage, when termination of BSAP
expression relieves the repression (46, 47, 55, 64). Several
groups have reported that a conserved BSAP site in the murine and human
germ line Ig
promoters is required for the LPS and IL-4 inducibility
of these promoters (39, 58, 67), but this finding has been
challenged (11). The parallels between Ig
germ line
transcription and class switching and RAG transcription are
intriguing: both can be induced by LPS and IL-4, and both take place in
the germinal center. BSAP may be an essential factor for both events.
Further support for a role for BSAP in RAG-2 reactivation in
the periphery comes from studies of IL-7 signaling. IL-7 was recently
shown to function as a cofactor for RAG reactivation in
cultured IgD+ splenic B cells, and administration of
antibody specific to the alpha chain of the IL-7 receptor (IL-7R
)
blocked the reactivation of the RAG genes in germinal center
B cells of immunized mice (33). Mice lacking the IL-7R
have a block in B-cell development at the same stage as BSAP-deficient
mice (V-to-DJ rearrangement), and BSAP transcript levels are reduced in
IL-7R
mutant animals (8). The functional consequences of
this reduction were demonstrated by reduced expression of the CD19 mRNA
and protein. These data suggest that BSAP functions downstream of an
IL-7 signaling pathway. RAG-2 reexpression in germinal
center B cells may depend on an IL-7-mediated increase in BSAP levels.
Receptor editing in the bone marrow and germinal center reexpression of
the RAG genes are two cases where the regulation of RAG transcription in B cells does not closely parallel that
in T cells. RAG transcription during the earliest stages of
B- and T-cell development might be regulated identically, with
B-cell-specific factors coming into play only at these later stages of
RAG expression. Alternatively, distinct mechanisms may
regulate the RAG genes in B and T cells throughout their
development, producing parallel expression in the two lineages during
early stages of development but diverging later on. In addition, it is
likely that other regulatory sequences besides the promoter are
important for controlling RAG-2 expression. Only the
elucidation of the complete repertoire of cis elements and
transcription factors regulating the RAG genes will allow us
to distinguish among these possibilities.
We thank Eugenia Spanopoulou for providing us with 293T cells and
the pEF-BOS expression vector, Meinrad Busslinger for sharing with us
anti-BSAP antisera, and Steven Desiderio and Patty Zwollo for providing
the BSAP cDNA. We thank Cynthia Guidos, Antony Rosen, David Schatz,
Robert Siliciano, and Stephen Smale for gifts of various cell lines. We
also thank Chi Dang for access to his luminometer and Qian-Fei Wang for
performing gel mobility shift analyses using recombinant BSAP. This
paper was improved by criticisms offered by Chi Dang and Kees Murre, by
various members of the Schlissel lab, and by anonymous reviewers.
M.S.S. acknowledges the support of NIH grant HL48702, the W. W. Smith Foundation, and the Leukemia Society of America. J.L. is a Howard
Hughes Medical Institute predoctoral fellow and a member of the
Biochemistry, Cellular and Molecular Biology Training Program at Johns Hopkins.